Intellia Aims Big with CRISPR Therapy to Cure ATTR

Intellia has received approval to launch their Phase I trial of NTLA-2001 in hereditary ATTR. Their NTLA-2001 candidate uses their proprietary non-viral lipid nanoparticle platform, which will deliver this CRISPR/Cas9-based therapy. Lipid nanoparticles are the most clinically advanced gene delivery system, overcoming nucleic acids delivery inefficiencies.